Contribute Try STAT+ Today

Searching for ways to beat back rising drug costs, the Chilean legislature is advancing three measures — regulating prices, easing the mechanism for issuing a compulsory license, and creating a government web site to monitor pricing —that have alarmed the pharmaceutical industry.

One of the initiatives in particular has drug makers concerned. The proposed law, which last week passed the Health Commission, will allow the government to determine the price of a patented medicine based on whether the buyers have “economic accessibility.” In other words, if the drug is priced out of reach, the health ministry will have the right to cap its price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.